Peroxisome proliferator-activated receptor gamma 1 (PPARγ1) (PPARγ1)

Peroxisome proliferator-activated receptor gamma 1 (PPARγ1) is a ligand-activated transcription factor and a member of the nuclear receptor superfamily [UniProt]. It is encoded by the PPARG gene and represents one of the two major isoforms produced through alternative splicing and promoter usage [PubMed]. While the PPARγ2 isoform is predominantly found in adipose tissue, PPARγ1 is more broadly expressed in tissues such as the liver, skeletal muscle, and colon [NCBI]. The receptor plays a fundamental role in regulating glucose and lipid metabolism, as well as adipocyte differentiation and inflammatory responses [PubMed]. Upon activation by natural ligands like fatty acids or synthetic drugs like thiazolidinediones, it heterodimerizes with the retinoid X receptor (RXR) to modulate gene expression [StatPearls]. In clinical medicine, PPARγ1 is a major therapeutic target for managing type 2 diabetes due to its ability to enhance insulin sensitivity [PubMed]. However, pharmacological activation of this receptor is associated with several adverse effects, including weight gain, fluid retention, and an increased risk of heart failure [StatPearls]. Research also continues to explore its potential in treating other conditions such as atherosclerosis and certain types of cancer [PubMed].

Other names

PPAR-gammaNR1C3Nuclear receptor subfamily 1 group C member 3PPARG1GLM1

Agonist binding to the ligand-binding domain of PPARγ1 induces a conformational change that promotes heterodimerization with the Retinoid X Receptor (RXR). This complex binds to Peroxisome Proliferator Response Elements (PPREs) in the promoter regions of target genes, recruiting co-activators to initiate the transcription of genes involved in glucose uptake, lipid storage, and insulin signaling [UniProt, StatPearls].